Nonsurgical treatment options for nonmelanoma skin cancers

Expert Review of Dermatology

Volumn 2, Issue 1, 2007, Pages 59-67

  Madan, Vishal ^a   Lear, John T ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; actinic keratosis; basal cell carcinoma; Bowen's disease; imiquimod; keratinocyte carcinoma; nonmelanoma skin cancer; photodynamic therapy; radiotherapy; retinoids; squamous cell carcinoma in situ

Indexed keywords

EID: 70149092255     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.2.1.59     Document Type: Article

References (54)

1. Holme SA, Malinovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988–98. Br. J. Dermatol. 143, 1224–1229 (2000).
2. Madan V, Hoban P, Strange RC, Fryer AA, Lear JT. Genetics and risk factors for basal cell carcinoma. Br. J. Dermatol. 154 (Suppl. 1), 5–7 (2006).
3. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27, 571–577 (2002).
4. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. Imiquimod in basal cell carcinoma: how does it work? Br. J. Dermatol. 149 (Suppl. 66), 57–58 (2003).
5. Berman B, Sullivan T, De Araujo T, Nadji M. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br. J. Dermatol. 149 (Suppl. 66), 59–61 (2003).
6. Schon M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl Cancer Inst. 95, 1138–1149 (2003).
7. Vidal D, Matias-Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin. Exp. Dermatol. 29, 518–525 (2004).
8. Peris K, Micantonio T, Fargnoli MC, Lozzi GP, Chimenti S. Imiquimod 5% cream in the treatment of Bowen’s disease and invasive squamous cell carcinoma. J. Am. Acad. Dermatol. 55, 324–327 (2006).
9. Patel GK, Goodwin R, Chawla M et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 54, 1025–1032 (2006).
10. Schulze HJ, Cribier B, Requena L et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled Phase III study in Europe. Br. J. Dermatol. 152, 939–947 (2005).
11. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two Phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol. 50, 722–733 (2004).
12. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch. Dermatol. 141, 985–993 (2005).
13. Bianchi L, Costanzo A, Campione E, Nistico S, Chimenti S. Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients. Clin. Exp. Dermatol. 28 (Suppl. 1), 24–26 (2003).
14. Huber A, Huber JD, Skinner RB Jr, Kuwahara RT, Haque R, Amonette RA. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol. Surg. 30, 429–430 (2004).
15. Quirk C, Gebauer K, Owens M, Stampone P. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas. J. Dermatol. 47, 258–265 (2006).
16. Shumack S, Robinson J, Kossard S et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch. Dermatol. 138, 1165–1171 (2002).
17. Sterry W, Ruzicka T, Herrera E et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br. J. Dermatol. 147, 1227–1236 (2002).
18. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch. Dermatol. 140, 1542 (2004).
19. Chen K, Yap LM, Marks R, Shumack S. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial Australas. J. Dermatol. 44, 250–255 (2003).
20. Korman N, Moy R, Ling M, Matheson R, Smith S. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two Phase III, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch. Dermatol. 141, 467–473 (2005).
21. Lebwohl M, Dinehart S, Whiting D et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two Phase III, randomized, double-blind, parallel group, vehicle-controlled trials J. Am. Acad. Dermatol. 50, 714–721 (2004).
22. Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical Imiquimod. NZ Med. J. 118, U1682 (2005).
23. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Mol. Immunol. 39, 1133–1136 (2003).
24. Morton CA. Photodynamic therapy for nonmelanoma skin cancer – and more? Arch. Dermatol. 140, 116–120 (2004).
25. Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of D-aminolevulinic acid methylester. Photochem. Photobiol. 68, 218–221 (1998).
26. Ackermann G, Abels C, Baumler W et al. Simulations on the selectivity of 5-aminolevulinic acid-induced fluorescence in vivo. J. Photochem. Photobiol. B. Biol. 47, 121–128 (1998).
27. Morton C, Horn M, Leman J et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch. Dermatol. 142, 729–735 (2006).
28. Szeimies RM, Morton CA, Sidoroff A, Braathen LR. Photodynamic therapy for non-melanoma skin cancer. Acta Derm. Venereol. 85, 483–490 (2005).
29. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol. Surg. 30, 264–271 (2004).
30. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br. J. Dermatol. 146, 552–567 (2002).
31. Wang I, Bendsoe N, Klinteberg CAF et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of. a phase III clinical trial. Br. J. Dermatol. 144, 832–840 (2001).
32. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch. Dermatol. 137, 319–324 (2001).
33. Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br. J. Dermatol. 148 (3), 539–543 (2003).
34. Lear JT, Wennberg AM, Schmook T et al. A multicentre study of photodynamic therapy with methly aminolevulinate (MAL-PDT) in immuno-compromised organ transplant recipients with non-melanoma skin cancer. Presented at: 15 EADV Congress, Rhodes, Greece, October 4–8, 2006.
35. Dragieva G, Hafner J, Dummer R et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients. Transplantation 77, 115–121 (2004).
36. Rhodes LE, de Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch. Dermatol. 140, 17–23 (2004).
37. Madan V, Loncaster J, Allan D et al. Systemic photodynamic therapy with photofrin for naevoid basal cell carcinoma syndrome-A pilot study. Photodiag. Photodynamic Ther. 2, 273–281 (2005).
38. Madan V, Loncaster JA, Allan D et al. Nodular basal cell carcinoma in Gorlin’s syndrome treated with systemic photodynamic therapy and interstitial optical fiber diffuser laser. J. Am. Acad. Dermatol. 55, S86 –S89 (2006).
39. Lui H, Hobbs L, Tope WD. Photodynamic therapy of multiple non melanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch. Dermatol. 140, 26–32 (2004).
40. Abdul Gaffar A, Lear JT. Epidermoid cysts post PDT. Clin. Exp. Derm. (In press).
41. Sturm HM. Bowen’s disease and 5-fluorouracil. J. Am. Acad. Dermatol. 16, 513–522 (1979).
42. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen’s disease. British Association of Dermatologists. Br. J. Dermatol. 141 (4) 633–641 (1999).
43. Stone N, Burge S. Bowen’s disease of the leg treated with weekly pulses of 5% fluorouracil cream. Br. J. Dermatol. 140, 987–988 (1999).
44. Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-fluorouracil. J. Cutan. Med. Surg. 7, 101–105 (2003).
45. Lambert T, Mullinax K, Smith JA. Case of an adverse reaction to topical 5-fluorouracil in irradiated skin. J. Drugs Dermatol. 5, 282–283 (2006).
46. Yesudian PD, King CM. Allergic contact dermatitis from stearyl alcohol in Efudix cream. Contact Dermatitis 45, 313–314 (2001).
47. Saif MW, Hashmi S, Mattison L, Donovan WB, Diasio RB. Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Anticancer Drugs 17, 1095–1098 (2006).
48. Locke J, Karimpour S, Young G, Lockett MA, Perez CA. Radiotherapy for epithelial skin cancer. Int. J. Radiat. Oncol. Biol. Phys. 51, 748–755 (2001).
49. Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int. J. Radiat. Oncol. Biol. Phys. 60, 406–411 (2004).
50. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br. J. Dermatol. 141, 415–423 (1999).
51. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int. J. Dermatol. 45, 489–498 (2006).
52. Maalej M, Frikha H, Kochbati L. Radio-induced malignancies of the scalp about 98 patients with 150 lesions and literature review. Cancer Radiother. 8, 81–87 (2004).
53. Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch. Dermatol. 141, 456–464 (2005).
54. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol. Surg. 32, 562–568 (2006).